Drug-Related Problems of Patients in Primary Health Care Institutions : A Systematic Review
Copyright © 2021 Ni, Yang, Bai, Hu and Zhang..
Introduction: Drug-related problems (DRPs) are not only detrimental to patients' physical health and quality of life but also lead to a serious waste of health care resources. The condition of DRPs might be more severe for patients in primary health care institutions. Objective: This systematic review aims to comprehensively review the characteristics of DRPs for patients in primary health care institutions, which might help find effective strategies to identify, prevent, and intervene with DRPs in the future. Methods: We searched three English databases (Embase, The Cochrane Library, and PubMed) and four Chinese databases (CNKI, CBM, VIP, and Wanfang). Two of the researchers independently conducted literature screening, quality evaluation, and data extraction. Qualitative and quantitative methods were combined to analyze the data. Results: From the 3,368 articles screened, 27 met the inclusion criteria and were included in this review. The median (inter-quartile range, IQR) of the incidences of DRPs was 70.04% (59%), and the median (IQR) of the average number of DRPs per patient was 3.4 (2.8). The most common type of DRPs was "treatment safety." The causes of DRPs were mainly in the prescribing section, including "drug selection" and "dose selection", while patients' poor adherence in the use section was also an important cause of DRPs. Risk factors such as the number of medicines, age, and disease condition were positively associated with the occurrence of DRPs. In addition, the medians (IQR) of the rate of accepted interventions, implemented interventions, and solved DRPs were 78.8% (22.3%), 64.15% (16.85%), and 76.99% (26.09%), respectively. Conclusion: This systematic review showed that the condition of DRPs in primary health care institutions was serious. In pharmaceutical practice, the patients with risk factors of DRPs should be monitored more closely. Pharmacists could play important roles in the identification and intervention of DRPs, and more effective intervention strategies need to be established in the future.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
---|---|
Enthalten in: |
Frontiers in pharmacology - 12(2021) vom: 06., Seite 698907 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ni, Xiao-Feng [VerfasserIn] |
---|
Links: |
---|
Themen: |
Drug-related problems |
---|
Anmerkungen: |
Date Revised 08.09.2021 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.3389/fphar.2021.698907 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM330320769 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM330320769 | ||
003 | DE-627 | ||
005 | 20231225211033.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3389/fphar.2021.698907 |2 doi | |
028 | 5 | 2 | |a pubmed24n1101.xml |
035 | |a (DE-627)NLM330320769 | ||
035 | |a (NLM)34489695 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ni, Xiao-Feng |e verfasserin |4 aut | |
245 | 1 | 0 | |a Drug-Related Problems of Patients in Primary Health Care Institutions |b A Systematic Review |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 08.09.2021 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a Copyright © 2021 Ni, Yang, Bai, Hu and Zhang. | ||
520 | |a Introduction: Drug-related problems (DRPs) are not only detrimental to patients' physical health and quality of life but also lead to a serious waste of health care resources. The condition of DRPs might be more severe for patients in primary health care institutions. Objective: This systematic review aims to comprehensively review the characteristics of DRPs for patients in primary health care institutions, which might help find effective strategies to identify, prevent, and intervene with DRPs in the future. Methods: We searched three English databases (Embase, The Cochrane Library, and PubMed) and four Chinese databases (CNKI, CBM, VIP, and Wanfang). Two of the researchers independently conducted literature screening, quality evaluation, and data extraction. Qualitative and quantitative methods were combined to analyze the data. Results: From the 3,368 articles screened, 27 met the inclusion criteria and were included in this review. The median (inter-quartile range, IQR) of the incidences of DRPs was 70.04% (59%), and the median (IQR) of the average number of DRPs per patient was 3.4 (2.8). The most common type of DRPs was "treatment safety." The causes of DRPs were mainly in the prescribing section, including "drug selection" and "dose selection", while patients' poor adherence in the use section was also an important cause of DRPs. Risk factors such as the number of medicines, age, and disease condition were positively associated with the occurrence of DRPs. In addition, the medians (IQR) of the rate of accepted interventions, implemented interventions, and solved DRPs were 78.8% (22.3%), 64.15% (16.85%), and 76.99% (26.09%), respectively. Conclusion: This systematic review showed that the condition of DRPs in primary health care institutions was serious. In pharmaceutical practice, the patients with risk factors of DRPs should be monitored more closely. Pharmacists could play important roles in the identification and intervention of DRPs, and more effective intervention strategies need to be established in the future | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a drug-related problems | |
650 | 4 | |a medication review | |
650 | 4 | |a pharmaceutical service | |
650 | 4 | |a primary health care | |
650 | 4 | |a systematic review | |
700 | 1 | |a Yang, Chun-Song |e verfasserin |4 aut | |
700 | 1 | |a Bai, Yu-Mei |e verfasserin |4 aut | |
700 | 1 | |a Hu, Zi-Xian |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Ling-Li |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Frontiers in pharmacology |d 2010 |g 12(2021) vom: 06., Seite 698907 |w (DE-627)NLM208568891 |x 1663-9812 |7 nnns |
773 | 1 | 8 | |g volume:12 |g year:2021 |g day:06 |g pages:698907 |
856 | 4 | 0 | |u http://dx.doi.org/10.3389/fphar.2021.698907 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 12 |j 2021 |b 06 |h 698907 |